Carolina D Schinke

List of Publications by Year
in descending order

122	1,819	304602	289141
papers	citations	22 h-index	40 g-index

125	125	125	3079
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Low expression of hexokinase-2 is associated with false-negative FDGâ€“positron emission tomography in multiple myeloma. Blood, 2017, 130, 30-34.	0.6	180
2	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood, 2016, 128, 1735-1744.	0.6	170
3	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood, 2015, 125, 3144-3152.	0.6	149
4	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical Cancer Research, 2017, 23, 1981-1987.	3.2	97
5	Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis. Journal of Immunology, 2013, 190, 2966-2975.	0.4	90
6	Aberrant DNA methylation in malignant melanoma. Melanoma Research, 2010, 20, 253-265.	0.6	88
7	The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood, 2018, 132, 59-66.	0.6	75
8	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Advances, 2020, 4, 422-431.	2.5	66
9	The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica, 2017, 102, e364-e367.	1.7	57
10	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature Communications, 2021, 12, 293.	5.8	54
11	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica, 2018, 103, 1047-1053.	1.7	47
12	Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology. Oncotarget, 2013, 4, 397-412.	0.8	40
13	BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical Cancer Research, 2020, 26, 2422-2432.	3.2	37
14	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American Journal of Hematology, 2017, 92, 739-745.	2.0	36
15	Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia, 2020, 34, 1866-1874.	3.3	36
16	Daratumumab in highâ€risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British Journal of Haematology, 2020, 189, 67-71.	1.2	35
17	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancer Research, 2016, 76, 4841-4849.	0.4	32
18	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical Cancer Research, 2018, 24, 2913-2919.	3.2	30

#	Article	IF	Citations
19	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer Journal, 2020, 10, 70.	2.8	27
20	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica, 2017, 102, e313-e316.	1.7	26
21	Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia, 2018, 32, 2435-2444.	3.3	26
22	The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. American Journal of Hematology, 2020, 95, E34-E35.	2.0	26
23	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood Cancer Journal, 2019, 9, 62.	2.8	23
24	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€"T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	2.8	22
25	Monitoring treatment response and disease progression in myeloma with circulating cellâ€free DNA. European Journal of Haematology, 2021, 106, 230-240.	1.1	21
26	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of Hematology and Oncology, 2020, 13, 108.	6.9	20
27	Mesenchymal stem cells gene signature in highâ€risk myeloma bone marrow linked to suppression of distinct IGFBP2â€expressing small adipocytes. British Journal of Haematology, 2019, 184, 578-593.	1.2	18
28	Cardiovascular complications of multiple myeloma in the elderly. Expert Review of Cardiovascular Therapy, 2017, 15, 933-943.	0.6	16
29	Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances, 2022, 6, 808-817.	2.5	14
30	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget, 2019, 10, 732-737.	0.8	13
31	The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, 2018, 132, 2775-2777.	0.6	12
32	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics, 2019, 9, 4756-4763.	4.6	12
33	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances, 2019, 3, 3962-3967.	2.5	12
34	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leukemia and Lymphoma, 2014, 55, 2901-2906.	0.6	11
35	Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma. Transplant Infectious Disease, 2016, 18, 939-941.	0.7	10
36	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of Bone and Mineral Research, 2017, 32, 1261-1266.	3.1	9

#	Article	IF	Citations
37	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers, 2021, 13, 4019.	1.7	9
38	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. Blood, 2016, 128, 4431-4431.	0.6	8
39	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood, 2016, 128, 4516-4516.	0.6	8
40	Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome Research, 2022, 32, 1343-1354.	2.4	8
41	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. Blood, 2015, 126, 20-20.	0.6	7
42	Design and synthesis of novel derivatives of all-transretinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PMLâ€“RAR-Î± oncogene in acute promyelocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1108-1114.	0.6	6
43	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. Immunotherapy, 2016, 8, 367-384.	1.0	6
44	Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transplant Infectious Disease, 2019, 21, e13052.	0.7	6
45	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, 2022, 36, 591-595.	3.3	6
46	Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. Blood, 2014, 124, 3602-3602.	0.6	6
47	Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of Clinical Medicine, 2022, 11, 1640.	1.0	6
48	PHF19 inhibition as a therapeutic target in multiple myeloma. Current Research in Translational Medicine, 2021, 69, 103290.	1.2	5
49	The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. Cancers, 2021, 13, 4909.	1.7	5
50	Firstâ€•versus secondâ€generation Bruton tyrosine kinase inhibitors in WaldenstrÃ¶m's Macroglobulinemia: A systematic review and metaâ€•analysis. American Journal of Hematology, 2022, 97, 942-950.	2.0	5
51	Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. Hematology Reports, 2017, 9, 7094.	0.3	4
52	Bone remineralization of lytic lesions in multiple myeloma â€“ The Arkansas experience. Bone, 2021, 146, 115876.	1.4	4
53	Persistent bone marrow minimal residual disease as a â€œhighâ€•riskâ€•disease feature in multiple myeloma. American Journal of Hematology, 2021, 96, E341-E344.	2.0	4
54	Highâ€•risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British Journal of Haematology, 2021, 195, 283-286.	1.2	4

#	Article	IF	Citations
55	EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. Blood, 2019, 134, 4569-4569.	0.6	4
56	Enrollment of Black Americans in Pivotal Clinical Trials Supporting Food and Drug Administration (FDA) Chimeric Antigen Receptor (CAR)-T Cell Therapy Approval in Hematological Malignancies. Blood, 2021, 138, 566-566.	0.6	4
57	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multiâ€institutional experience. American Journal of Hematology, 2022, 97, .	2.0	4
58	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone, 2019, 121, 134-138.	1.4	3
59	Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma. Blood, 2018, 132, 408-408.	0.6	3
60	Late Relapsing Multiple Myeloma â‰¥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome. Blood, 2020, 136, 11-12.	0.6	3
61	Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes. Blood, 2008, 112, 595-595.	0.6	3
62	A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. American Journal of Case Reports, 2016, 17, 173-176.	0.3	3
63	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, 106, 0-0.	1.7	2
64	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. Leukemia Research, 2021, 110, 106714.	0.4	2
65	The Mutational Landscape of Primary Plasma Cell Leukemia. Blood, 2018, 132, 114-114.	0.6	2
66	Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma. Blood, 2019, 134, 4333-4333.	0.6	2
67	Mir-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-b Signaling,. Blood, 2011, 118, 3813-3813.	0.6	2
68	Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes. Blood, 2012, 120, 924-924.	0.6	2
69	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Blood, 2015, 126, 2979-2979.	0.6	2
70	Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.. Journal of Clinical Oncology, 2020, 38, 8514-8514.	0.8	2
71	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. Blood, 2015, 126, 3181-3181.	0.6	2
72	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. Blood, 2016, 128, 115-115.	0.6	2

#	Article	IF	Citations
73	Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups. Blood, 2019, 134, 3309-3309.	0.6	2
74	Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission. Blood, 2020, 136, 44-44.	0.6	2
75	CAâ€125 secreting IgG kappa multiple myeloma. American Journal of Hematology, 2016, 91, E457-8.	2.0	1
76	Clinical characteristics of testicular extramedullary involvement in multiple myeloma. American Journal of Hematology, 2021, 96, E77-E81.	2.0	1
77	Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2021, 39, e20031-e20031.	0.8	1
78	Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood, 2018, 132, 110-110.	0.6	1
79	Design and Synthesis of Novel Derivatives of ATRA Demonstrate the Combined Importance of Acid Moiety and Conjugated Double Bonds in Its Binding to PMLRAR-Alpha Oncogene in Acute Promyelocytic Leukemia. Blood, 2008, 112, 5036-5036.	0.6	1
80	Inhibition Of CXCR2 As a Therapeutic Strategy In AML and MDS. Blood, 2013, 122, 484-484.	0.6	1
81	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2014, 124, 2128-2128.	0.6	1
82	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). Blood, 2015, 126, 1843-1843.	0.6	1
83	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Blood, 2015, 126, 369-369.	0.6	1
84	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. Blood, 2016, 128, 2065-2065.	0.6	1
85	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. Blood, 2016, 128, 3266-3266.	0.6	1
86	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood, 2016, 128, 377-377.	0.6	1
87	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Blood, 2015, 126, 3182-3182.	0.6	1
88	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. Blood, 2016, 128, 117-117.	0.6	1
89	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. Blood, 2016, 128, 4416-4416.	0.6	1
90	Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance. Blood, 2018, 132, 4465-4465.	0.6	1

#	Article	IF	Citations
91	Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. Blood, 2018, 132, 1906-1906.	0.6	1
92	An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome. Blood, 2018, 132, 4489-4489.	0.6	1
93	Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Blood, 2021, 138, 4110-4110.	0.6	1
94	An Outbreak of Respiratory Syncytial Virus Infections in an Outpatient Cancer Unit: Clinical Characteristics and Molecular Investigations. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
95	Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e59-e60.	0.2	0
96	Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia. Blood, 2011, 118, 5008-5008.	0.6	0
97	Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2014, 124, 4628-4628.	0.6	0
98	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. Blood, 2015, 126, 724-724.	0.6	0
99	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 5395-5395.	0.6	0
100	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Blood, 2015, 126, 4193-4193.	0.6	0
101	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. Blood, 2016, 128, 2064-2064.	0.6	0
102	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. Blood, 2016, 128, 4438-4438.	0.6	0
103	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. Blood, 2018, 132, 4457-4457.	0.6	0
104	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. Blood, 2018, 132, 4441-4441.	0.6	0
105	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. Blood, 2018, 132, 4468-4468.	0.6	0
106	Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria. Blood, 2018, 132, 4456-4456.	0.6	0
107	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. Blood, 2018, 132, 3185-3185.	0.6	0
108	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. Blood, 2018, 132, 4471-4471.	0.6	0

#	Article	IF	Citations
109	Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes. Blood, 2018, 132, 4448-4448.	0.6	0
110	Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors. Blood, 2018, 132, 1929-1929.	0.6	0
111	The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells. Blood, 2019, 134, 4412-4412.	0.6	0
112	The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 508-508.	0.6	0
113	Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker. Blood, 2019, 134, 4370-4370.	0.6	0
114	The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells. Blood, 2019, 134, 4390-4390.	0.6	0
115	Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance. Blood, 2021, 138, 2713-2713.	0.6	0
116	Deep Profiling of the Immune Microenvironment throughout Myeloma Disease Stages. Blood, 2021, 138, 727-727.	0.6	0
117	Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome. Blood, 2021, 138, 1627-1627.	0.6	0
118	Synchronous plasma cell neoplasm and B lymphoblastic leukemia/lymphoma at initial presentation: first report of an unusual association with a good outcome. Journal of Hematopathology, 0, , 1.	0.2	0
119	Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma. Blood, 2020, 136, 2-2.	0.6	0
120	Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American Journal of Hematology, 2022, 97, .	2.0	0
121	Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 2021, , .	1.7	0
122	Gender disparities in multiple myeloma publications.. Journal of Clinical Oncology, 2022, 40, e23000-e23000.	0.8	0